AI pharmaceutical trend swept the world, and the Chinese AI Pharmaceutical Corporation is still chasing

Smart Bud Innovation Research Center/Jiang Wen

The emergence of AI pharmaceutical technology provides new solutions for the development of new drugs to "reduce costs and increase efficiency", which is considered to be expected to subvert traditional pharmaceutical rules. In recent years, the AI ​​pharmaceutical track has continued to heat up, science and technology enterprises have sprung up, and Internet giants have ended their positions. Cross -border competition and capital strikes are staged. How is Chinese enterprise developing on the AI ​​pharmaceutical track?

Smart bud believes that the global AI pharmaceutical has entered the clinical advancement phase of AI design drugs from the 1.0 technology accumulation stage in the past ten years. In recent years, Chinese AI Pharmaceutical Sciences Enterprises have shocked in terms of AI technology capabilities and drug research and development capabilities. Some companies have also made good progress in the clinical advancement of AI design drugs.

1. In the past ten years, global AI pharmaceuticals have entered the 3.0 stage from 1.0, and industry potential has erupted

With the development time of AI pharmaceutical development, the development process of global AI pharmaceutical companies can be divided into three stages, which began in the 1.0 technology accumulation stage of 2013. At this stage, companies are mainly technical accumulation and technical services. Entering the 2.0 self -developed pipeline stage, more and more enterprises have basically completed the accumulation of previous technical accumulation, and the cooperation of the big factories in the hands of the factory began to develop the pipeline. Since 2020, 3.0 has entered the clinical stage. Ai AI Pharmaceuticals move to application and move into the 3.0 stage.

With the gradual maturity of the three stages of AI pharmaceutical technology and R & D model, the popularity of the capital market has also shown a significant upward trend. According to the Smart Bud Discovery Database, from 2013 to 2021, the number of investment and financing in the field of AI pharmaceuticals increased from less than 100 from 2013 to nearly 400, an increase of nearly 4 times; From 600. More than 50%of the financing occurred in the United States. According to the data, my country's AI Pharmaceutical Company Jingtai Technology completed a large amount of financing of $ 300 million in 2020. In 2021, AI Pharmaceutical Company Insitro's 400 million US dollars C financing has become a company with the highest amount of financing in the world in the world's AI pharmaceutical field Essence

Figure 1 Global AI Pharmaceutical Investment and Financing Trends (Data Source: Smart Bud Discovery)

2. Although China AI Pharmaceutical and Innovation Enterprises have started late, in recent years

Since the overseas leading AI pharmaceutical science and technology innovation enterprises have entered the 3.0 stage in 2020, what kind of pace will the Chinese AI pharmaceutical innovation enterprise go out? In the following, we compare and analyze the technical capabilities of 60 major AI pharmaceutical companies and 39 overseas AI pharmaceutical companies overseas. Among them, 60 major AI pharmaceutical companies in China reference to the Smart Pharmaceutical Bureau of the Think Tank Platform, including Jingtai Technology, Unknown Jun, Fermiko Technology, Starbang Original Bio, Udao Bio, etc. The list of platforms compiled by platforms such as DEEP KNowledge Analytics and Zhiyaobang, including recursion pharmaceuticals, Benevolent.al, ExSCientia, etc., and refer to the data description at the end of the article at home and abroad.

According to the smart bud patented database, the Chinese AI pharmaceutical innovation enterprise started late, and there is still a significant gap in the leading AI pharmaceutical innovation enterprise overseas in technology reserves. The average number of domestic AI pharmaceutical innovation enterprises has an average of about 10 patent applications, which is one -fifth of the average number of patent applications for overseas AI pharmaceutical innovation enterprises.

Figure 2 Comparison of patent application trends in the field of AI pharmaceuticals in the past 20 years (data source: smart bud)

AI Pharmaceutical is a typical multidisciplinary cross -area. We will define a series of technologies such as prediction method/model establishment, big data processing, cloud computing and other series of technologies as AI technology capabilities, and define drug chemistry, molecular chemistry and other technologies as drug research and development skills. Further compares companies in AI technology and drug research and development capabilities respectively.

In terms of AI technology capabilities, domestic AI pharmaceutical innovation enterprises have started late, and the growth rate of technology development is higher than overseas enterprises. In the past seven years (from 2013 to 2020), domestic AI pharmaceutical science and technology enterprises have increased their average annual growth rate in AI pharmaceutical technology. Up to 54%, higher than 34%of the annual growth rate of overseas companies. In terms of pharmaceutical research and development capabilities, domestic AI pharmaceutical innovation enterprises present similar characteristics and have developed late, but in recent years, it has grown faster than overseas companies. The average annual growth rate of the past seven years is about 48%. The average annual growth rate is 4 times.

Figure 3 In the past 20 years, the technological development trend of Chinese AI pharmaceutical science and technology enterprises in AI technology and drug research and development (data source: smart bud)

Figure 4 The leading science and technology enterprise of some AI pharmaceuticals overseas in the past 20 years in the technological development trend of AI technology and drug research and development

(Data source: smart bud)

Compared with the technological development trend of the AI ​​pharmaceutical innovation enterprises at home and abroad, although China's AI Pharmaceuticals and Pharmaceutical Capitals have started late and the technical reserves are still different from overseas leading enterprises, the growth is on the rise.

3. China AI Pharmaceutical Science and Technology Enterprise has not yet formed a scale effect in clinical experiments

For AI pharmaceutical innovation enterprises, under the business model, it is an inevitable trend to do medicine. This is mainly due to the profit problem of AI pharmaceutical science and technology innovation enterprises in CRO models. Although AI pharmaceutical companies in the CRO model have increased the possibility of pharmaceutical companies, they still need a series of animal experiments and clinical experiments to verify whether the drugs are true and feasible, which leads to the current willingness to pay for pharmaceutical companies. Public information shows that a 2 million yuan order is high in the industry, and the vast majority of AI pharmaceutical companies receive a few orders a year. However, the end of the medicine for AI pharmaceutical companies has proposed a series of tests from clinical to follow -up service capabilities, and Chinese companies have not yet entered systematic progress.

Further combined with the smart bud Pharmsnap data, we can see that my country's AI pharmaceutical science and technology enterprises are promoted in drug trials. Only a few companies have AI designed drugs to enter the clinical stage. Drugs that have been approved into the clinic and unknown king are XBI-302. Combined with public information, as of the end of 2021, 39 of 39 overseas leading AI pharmaceutical companies had 35 drugs entering clinical trials, and about 2 drugs per company entered the clinical stage. On the whole, my country's AI pharmaceutical science and technology enterprises lag behind overseas in the clinical stage of drug advancement.

Judging from the results of new drugs in AI, Chinese companies have not yet been designed for the first innovative medicine through AI. In contrast, the development experience of overseas leading AI pharmaceutical companies, overseas companies have made breakthrough progress. It is particularly worth mentioning that in 2021, Yingsilia Smart announced the clinical research pipeline (codenamed ISM001-055). The first candidate medicine with new targets and new molecular structure discovered by artificial intelligence.

Based on the above, on the AI ​​pharmaceutical track with broad prospects, although my country's AI pharmaceutical innovation enterprises have grown rapidly in recent years, there is still a gap in overseas leading companies in terms of technical reserves, source innovation, and clinical advancement. However, since 2020, technology Internet companies represented by BAT, Huawei, byte beating, etc. have deployed the field of AI new drug research and development, or launched drug discovery platforms, or recruiting AI drug research and development talents. The new drug research and development industry may move towards a new stage of development.

the data shows:

1) Statistics of cumulative patents as of May 13, 2022.

2) Patent statistics at the enterprise level adopt the principle of completely "parallelism". The company's tree function of the smart bud global patent database is used, and all the patents of all the companies controlled by the President of Hui.

3) Smart Bud Global Patent Database continues to dynamically include public patents in 158 countries/regions around the world. Generally speaking, patents can be queried from applying to public, which takes 4 to 18 months, so the data in the past two years is only for reference.

- END -